{"entity":{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","aka":[],"tldr":"GT Medical Technologies makes GammaTile, small dissolvable collagen tiles containing radioactive caesium seeds that a neurosurgeon places in the cavity left after removing a brain tumour, so radiation starts immediately and the patient avoids weeks of daily radiotherapy visits.","summary":"GT Medical Technologies (Tempe, Arizona), founded by brain tumour specialists, developed GammaTile, an FDA-cleared bioresorbable brachytherapy implant. Collagen tiles carrying caesium-131 seeds are placed in the resection cavity at surgery, delivering a localised dose over the following weeks. GammaTile is indicated for newly diagnosed malignant and recurrent intracranial neoplasms, had its full US launch in March 2020. The randomised phase 3 ROADS trial in newly diagnosed brain metastases, presented at ASCO 2026, compared resection plus GammaTile with resection plus post-operative stereotactic radiotherapy; the company reports a 93 percent lower risk of local recurrence and 41 percent lower risk of death at 12 months without added toxicity. The BRIDGES randomised trial in newly diagnosed glioblastoma is enrolling. In June 2026 the company closed an oversubscribed USD 100 million Series E led by Viking Global Investors.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://gammatile.com/"},{"label":"Series E press release (June 2026)","url":"https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html"},{"label":"About GT Medical Technologies","url":"https://gammatile.com/about-gt-medical-technologies/"},{"label":"ROADS phase 3 results at ASCO 2026","url":"https://www.prnewswire.com/news-releases/roads-phase-3-clinical-trial-data-presented-at-asco26-show-gammatile-provides-superior-tumor-control-leading-to-patients-living-longer-without-recurrence-compared-to-standard-of-care-in-newly-diagnosed-operable-brain-metastases-302786198.html"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":["radiation","surgery","devices"],"technologies":["brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04365374","nct07195591"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["gtmedtech.com redirects to gammatile.com, which is used as the canonical website. Founding year and Series A to D rounds are unsourced and omitted. The Cs-131 half-life and tile dimensions are from general knowledge, not the fetched pages. The ROADS ASCO release URL was confirmed reachable (HTTP 200)."],"hq":"Tempe, AZ","country":"US","companyType":"devices","website":"https://gammatile.com/","stage":"growth","investors":["gilde-healthcare"],"funding":[{"round":"Series E","year":2026,"amountUsd":100000000,"source":"https://www.prnewswire.com/news-releases/gt-medical-technologies-completes-oversubscribed-100-million-series-e-equity-financing-to-advance-commercial-treatment-for-patients-with-operable-brain-tumors-302794352.html","note":"Oversubscribed; led by new investor Viking Global Investors"}]},"route":"/companies/gt-medical-technologies/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"section":[{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"}],"trial":[{"id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/"},{"id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/"}],"company":[{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/"}]}}